Jasper Therapeutics Inc. (JSPR)

$0.59 +0.01 (1.63%)
Market Cap 14.41M
Revenue (ttm) 0.00
Net Income (ttm) -75.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,308,636
Avg Vol 490,644
Day's Range N/A - N/A
Shares Out 28.00M
Stochastic %K 95%
Beta 3.07
Analysts Sell
Price Target $7.50

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chroni...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 549 1400
Address:
2200 Bridge Pkwy, Suite 102, Redwood City, United States
30PERCENT40
30PERCENT40 Jul. 10 at 5:56 PM
$JSPR I see you...🤑🤑🤑🤑
1 · Reply
FIREINSP
FIREINSP Jul. 10 at 5:37 PM
$JSPR Decent volume…
0 · Reply
Biobio4
Biobio4 Jul. 10 at 3:20 PM
$JSPR news coming ?
0 · Reply
NNTrader
NNTrader Jul. 10 at 3:14 PM
$JSPR something is coming
0 · Reply
NNTrader
NNTrader Jul. 10 at 1:58 PM
$JSPR bullish
1 · Reply
Bullshyte
Bullshyte Jul. 10 at 1:42 PM
$JSPR Insane opportunity down here...
1 · Reply
Biotech41
Biotech41 Jul. 10 at 8:09 AM
$JSPR a bit more of recovery today please :)
0 · Reply
buttercup1007
buttercup1007 Jul. 10 at 2:44 AM
$JSPR up 25% this past week, steady climb
0 · Reply
NeonRaider
NeonRaider Jul. 10 at 1:32 AM
$JSPR multi day runner
0 · Reply
Bullshyte
Bullshyte Jul. 8 at 8:47 PM
$JSPR Very
1 · Reply
Latest News on JSPR
Jasper Therapeutics Proxy statement: Proxy filing

Jun 15, 2026, 8:00 AM EDT - 25 days ago

Jasper Therapeutics Proxy statement: Proxy filing

Jasper Therapeutics Proxy statement: Proxy filing

Jun 15, 2026, 8:00 AM EDT - 25 days ago

Jasper Therapeutics Proxy statement: Proxy filing

Jasper Therapeutics initiates review of strategic alternatives

2026-06-01T12:26:26.000Z - 5 weeks ago

Jasper Therapeutics initiates review of strategic alternatives

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Jun 1, 2026, 8:00 AM EDT - 5 weeks ago

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Jasper Therapeutics price target lowered to $3 from $4 at RBC Capital

2026-05-15T13:18:13.000Z - 2 months ago

Jasper Therapeutics price target lowered to $3 from $4 at RBC Capital

Jasper Therapeutics downgraded to Hold from Buy at TD Cowen

2026-05-15T09:40:09.000Z - 2 months ago

Jasper Therapeutics downgraded to Hold from Buy at TD Cowen

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 4:05 PM EDT - 2 months ago

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jasper Therapeutics Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 2 months ago

Jasper Therapeutics Quarterly report: Q1 2026

Jasper Therapeutics Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 2 months ago

Jasper Therapeutics Earnings release: Q1 2026

Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI

2026-04-01T11:59:40.000Z - 3 months ago

Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI

Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)

2026-03-30T20:37:13.000Z - 3 months ago

Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Mar 30, 2026, 4:30 PM EDT - 3 months ago

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Jasper Therapeutics Earnings release: Q4 2025

Jasper Therapeutics Annual report: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Jasper Therapeutics Annual report: Q4 2025

Jasper Therapeutics assumed with a Neutral at UBS

2026-03-23T10:20:58.000Z - 3 months ago

Jasper Therapeutics assumed with a Neutral at UBS

Jasper Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 3:50 PM EST - 4 months ago

Jasper Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Jasper Therapeutics Slides: Corporate presentation

Mar 2, 2026, 7:00 AM EST - 4 months ago

Jasper Therapeutics Slides: Corporate presentation

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

Feb 24, 2026, 4:30 PM EST - 4 months ago

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

Jasper Therapeutics initiated with a Buy at Rodman & Renshaw

2026-01-13T20:20:15.000Z - 6 months ago

Jasper Therapeutics initiated with a Buy at Rodman & Renshaw

Jasper Therapeutics Transcript: Study Result

Jan 8, 2026, 8:00 AM EST - 6 months ago

Jasper Therapeutics Transcript: Study Result

Jasper Therapeutics Press release: Study Result

Jan 8, 2026, 8:00 AM EST - 6 months ago

Jasper Therapeutics Press release: Study Result

Jasper Therapeutics Slides: Study Result

Jan 8, 2026, 8:00 AM EST - 6 months ago

Jasper Therapeutics Slides: Study Result

Jasper Therapeutics reports updated data from briquilimab studies

2026-01-08T12:15:17.000Z - 6 months ago

Jasper Therapeutics reports updated data from briquilimab studies

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Jan 8, 2026, 7:00 AM EST - 6 months ago

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Jasper Therapeutics says Jeet Mahal to succeed Ronald Martell as CEO

2026-01-07T21:35:34.000Z - 6 months ago

Jasper Therapeutics says Jeet Mahal to succeed Ronald Martell as CEO

Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

Jan 7, 2026, 4:30 PM EST - 6 months ago

Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

3 Penny Stocks to Watch Now, 12/4/25

2025-12-04T16:57:00.000Z - 7 months ago

3 Penny Stocks to Watch Now, 12/4/25

BQ

Jasper Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 3:00 PM EST - 7 months ago

Jasper Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Jasper Therapeutics Transcript: Study Result

Dec 2, 2025, 8:00 AM EST - 7 months ago

Jasper Therapeutics Transcript: Study Result

Jasper Therapeutics Press release: Study Result

Dec 2, 2025, 8:00 AM EST - 7 months ago

Jasper Therapeutics Press release: Study Result

Jasper Therapeutics Slides: Study Result

Dec 2, 2025, 8:00 AM EST - 7 months ago

Jasper Therapeutics Slides: Study Result

Jasper Therapeutics reports data from ETESIAN Phase 1b study

2025-12-02T12:10:33.000Z - 7 months ago

Jasper Therapeutics reports data from ETESIAN Phase 1b study

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Dec 2, 2025, 7:00 AM EST - 7 months ago

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Dec 1, 2025, 4:30 PM EST - 7 months ago

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Jasper Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 3:30 PM EST - 8 months ago

Jasper Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Jasper Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 4:00 PM EST - 8 months ago

Jasper Therapeutics Transcript: Stifel 2025 Healthcare Conference

Jasper Therapeutics Slides: Investor Presentation

Nov 11, 2025, 7:00 AM EST - 8 months ago

Jasper Therapeutics Slides: Investor Presentation

Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29)

2025-11-10T13:05:12.000Z - 8 months ago

Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29)

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 10, 2025, 8:00 AM EST - 8 months ago

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 8:00 AM EST - 8 months ago

Jasper Therapeutics Quarterly report: Q3 2025

Jasper Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 8:00 AM EST - 8 months ago

Jasper Therapeutics Earnings release: Q3 2025

Jasper Therapeutics Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 8 months ago

Jasper Therapeutics Slides: Corporate Presentation

Jasper Therapeutics to Present at Upcoming Investor Conferences

Nov 4, 2025, 8:00 AM EST - 8 months ago

Jasper Therapeutics to Present at Upcoming Investor Conferences

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)

Sep 22, 2025, 1:05 PM EDT - 10 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)

Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMP

2025-09-22T10:55:06.000Z - 10 months ago

Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMP

Jasper Therapeutics 11.67M share Spot Secondary priced at $2.43

2025-09-19T10:00:28.000Z - 10 months ago

Jasper Therapeutics 11.67M share Spot Secondary priced at $2.43

Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Sep 19, 2025, 12:07 AM EDT - 10 months ago

Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Jasper Therapeutics announces common stock offering, no amount given

2025-09-18T20:15:24.000Z - 10 months ago

Jasper Therapeutics announces common stock offering, no amount given

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Sep 18, 2025, 4:08 PM EDT - 10 months ago

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Jasper Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 1:00 PM EDT - 11 months ago

Jasper Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Jasper Therapeutics Slides: Corporate Presentation

Sep 2, 2025, 6:00 PM EDT - 11 months ago

Jasper Therapeutics Slides: Corporate Presentation

Jasper Therapeutics price target lowered to $25 from $29 at UBS

2025-08-15T11:35:55.000Z - 11 months ago

Jasper Therapeutics price target lowered to $25 from $29 at UBS

Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)

2025-08-13T20:35:13.000Z - 11 months ago

Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 11 months ago

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 11 months ago

Jasper Therapeutics Earnings release: Q2 2025

Jasper Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 11 months ago

Jasper Therapeutics Quarterly report: Q2 2025

Jasper Therapeutics to reduce workforce by 50%, focus on Chronic Urticaria

2025-07-09T12:15:18.000Z - 1 year ago

Jasper Therapeutics to reduce workforce by 50%, focus on Chronic Urticaria

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

RBC downgrades Jasper Therapeutics on questions about briquilimab

2025-07-08T10:25:33.000Z - 1 year ago

RBC downgrades Jasper Therapeutics on questions about briquilimab

CLDX

Jasper Therapeutics price target lowered to $12 from $70 at Citizens JMP

2025-07-08T09:45:23.000Z - 1 year ago

Jasper Therapeutics price target lowered to $12 from $70 at Citizens JMP

Jasper Therapeutics Transcript: Study Update

Jul 7, 2025, 8:30 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Study Update

Jasper Therapeutics Press release: Study Update

Jul 7, 2025, 8:30 AM EDT - 1 year ago

Jasper Therapeutics Press release: Study Update

Jasper Therapeutics Slides: Study Update

Jul 7, 2025, 8:30 AM EDT - 1 year ago

Jasper Therapeutics Slides: Study Update

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jul 7, 2025, 7:30 AM EDT - 1 year ago

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jasper Therapeutics Slides: Investor Presentation

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Jasper Therapeutics Slides: Investor Presentation

Jasper Therapeutics Transcript: Status Update

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Status Update

Jasper Therapeutics Press release: Status Update

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Press release: Status Update

Jasper Therapeutics Slides: Status Update

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Slides: Status Update

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jun 14, 2025, 10:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jasper Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

Jasper Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 21, 2025, 11:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

Jasper Therapeutics Proxy statement: Proxy Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Proxy statement: Proxy Filing

Jasper Therapeutics Proxy statement: Proxy Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Proxy statement: Proxy Filing

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 4:05 PM EDT - 1 year ago

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

Jasper Therapeutics Earnings release: Q1 2025

Jasper Therapeutics Quarterly report: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

Jasper Therapeutics Quarterly report: Q1 2025

Jasper Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 27, 2025, 12:30 PM EDT - 1 year ago

Jasper Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Jasper Therapeutics Registration statement: Registration Filing

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Registration statement: Registration Filing

Jasper Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 1:20 PM EST - 1 year ago

Jasper Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Mar 1, 2025, 12:45 PM EST - 1 year ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Jasper Therapeutics Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Annual report: Q4 2024

Jasper Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Earnings release: Q4 2024

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 25, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 10, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Feb 4, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jasper Therapeutics Transcript: Study Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Transcript: Study Update

Jasper Therapeutics Press release: Study Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Press release: Study Update

Jasper Therapeutics Slides: Study Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Slides: Study Update

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 8, 2025, 7:00 AM EST - 1 year ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Jan 6, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Jasper Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 3, 2024, 3:25 PM EST - 1 year ago

Jasper Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Dec 2, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Jasper Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 9:45 AM EST - 1 year ago

Jasper Therapeutics Transcript: Stifel 2024 Healthcare Conference

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 13, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Jasper Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Earnings release: Q3 2024

Jasper Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Quarterly report: Q3 2024

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Jasper Therapeutics Transcript: Study Result

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Study Result

Jasper Therapeutics Press release: Study Result

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Press release: Study Result

Jasper Therapeutics Slides: Study Result

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Slides: Study Result

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jasper Therapeutics Transcript: TD Cowen Chronic Urticaria Summit

Sep 20, 2024, 12:00 PM EDT - 1 year ago

Jasper Therapeutics Transcript: TD Cowen Chronic Urticaria Summit

Jasper Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 2:30 PM EDT - 1 year ago

Jasper Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Jasper Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 10, 2024, 3:00 PM EDT - 1 year ago

Jasper Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Jasper Therapeutics Slides: Corporate Presentation

Sep 10, 2024, 6:00 AM EDT - 1 year ago

Jasper Therapeutics Slides: Corporate Presentation

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

Sep 4, 2024, 4:30 PM EDT - 2 years ago

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

30PERCENT40
30PERCENT40 Jul. 10 at 5:56 PM
$JSPR I see you...🤑🤑🤑🤑
1 · Reply
FIREINSP
FIREINSP Jul. 10 at 5:37 PM
$JSPR Decent volume…
0 · Reply
Biobio4
Biobio4 Jul. 10 at 3:20 PM
$JSPR news coming ?
0 · Reply
NNTrader
NNTrader Jul. 10 at 3:14 PM
$JSPR something is coming
0 · Reply
NNTrader
NNTrader Jul. 10 at 1:58 PM
$JSPR bullish
1 · Reply
Bullshyte
Bullshyte Jul. 10 at 1:42 PM
$JSPR Insane opportunity down here...
1 · Reply
Biotech41
Biotech41 Jul. 10 at 8:09 AM
$JSPR a bit more of recovery today please :)
0 · Reply
buttercup1007
buttercup1007 Jul. 10 at 2:44 AM
$JSPR up 25% this past week, steady climb
0 · Reply
NeonRaider
NeonRaider Jul. 10 at 1:32 AM
$JSPR multi day runner
0 · Reply
Bullshyte
Bullshyte Jul. 8 at 8:47 PM
$JSPR Very
1 · Reply
NNTrader
NNTrader Jul. 8 at 3:01 PM
$JSPR re-entered
2 · Reply
Jdog100000000
Jdog100000000 Jul. 8 at 2:57 PM
$AMC $JSPR $OMEX $SPCX red because it’s dead. Don’t listen to this pumper piece of shit. His average is probably 1.60
0 · Reply
Innerchild
Innerchild Jul. 8 at 2:55 PM
$OMEX Entire market is red, Omex is holding strong, and it’s about to skyrocket with you or wihout you, so keep whining. $SPCX $AMC $JSPR
0 · Reply
buttercup1007
buttercup1007 Jul. 8 at 2:43 PM
$JSPR dteady climb in an otherwise red day
0 · Reply
shehww
shehww Jul. 8 at 2:43 PM
$JSPR any news?
0 · Reply
NarutoBreakouts
NarutoBreakouts Jul. 7 at 8:44 PM
$AKTX $FATE $RGNX $JSPR Ther
0 · Reply
FIREINSP
FIREINSP Jul. 7 at 11:58 AM
$JSPR Any news on this? Been a good week for them as of late.
0 · Reply
Gadotti777
Gadotti777 Jun. 30 at 12:18 PM
$JSPR @FIREINSP Your comment would be entirely correct if the individuals on this company's board weren't so highly respected in the market and didn't possess such extensive track records of major deals. If you look into it, this company has invested far more in top-tier talent than others in the sector—and, it must be said, these are heavyweights in the market. That is why I have great confidence in this case.
1 · Reply
FIREINSP
FIREINSP Jun. 29 at 9:37 PM
$JSPR This smells of a rug pull…
0 · Reply
topstockalerts
topstockalerts Jun. 29 at 9:25 PM
$JSPR this has that “don’t overthink it” look.
0 · Reply
Hotrod49
Hotrod49 Jun. 29 at 8:00 PM
$JSPR $5.00
1 · Reply
Hotrod49
Hotrod49 Jun. 29 at 8:00 PM
$JSPR nice and easy baby
0 · Reply